Kolmar Korea, a cosmetics ODM (original design manufacturing) specialist, saw its stock price surge over 31% during the week of June 26 to July 2, bringing year-to-date gains to approximately 38%. Securities firms forecast the company will deliver an earnings surprise in Q2 2025, driven by explosive sales growth at its core Korean production subsidiary—analysts estimate Korean subsidiary sales will rise 25–26% with operating profit margin reaching a record-high 15% as suncare and skincare orders from top clients flooded in. The rally reflects strong fundamentals in K-beauty's global expansion and the summer suncare peak season.
Kolmar Korea Forecasts Record Q2 Operating Margin at Korean Subsidiary
Shinhan Investment Securities and Kyobo Securities projected Korean subsidiary sales growth of at least 25% and 26% respectively, with operating profit margin (OPM) expected to reach the 15% range—an all-time high for the company. Park Hyun-jin, a Shinhan Investment Securities analyst, stated that increased production of basic cosmetics at the Korean manufacturing entity is improving product mix and amplifying profit margins. Shinhan Investment maintained a 'Buy' rating on Kolmar Korea stocks and raised the target price from 123,000 won to 130,000 won. Other brokerages set target prices as high as 140,000 won.
Analysts noted that Kolmar Korea is breaking away from the traditional seasonal pattern where Q2 marks the annual peak due to suncare pre-orders, followed by a slowdown in the second half. This year, robust order flow is expected to continue through Q3 as K-beauty distribution expands into US offline channels and European markets. Kwon Woo-jung, a Kyobo Securities analyst, observed that the top client maintained strong momentum in Q2 with suncare seasonality and expanded skincare sales, and that multiple ODM companies' Korean subsidiaries are seeing sequential order increases—indicating weakened seasonality and a shift away from past assumptions.
FDA Approves Bemotrizinol for Sunscreen Products After 27 Years
On the 9th of last month, the US Food and Drug Administration (FDA) granted final approval for the use of Bemotrizinol in over-the-counter (OTC) sunscreen products—the first new active UV filter ingredient approved in 27 years. Bemotrizinol is a high-performance organic UV filter that effectively blocks both UVA (which causes skin aging) and UVB (which causes sunburn), and has been widely used in Europe and Asia. Kolmar Korea has accumulated global-level clinical data, regulatory compliance capabilities, and quality control expertise in formulating and manufacturing sunscreens with this ingredient. Analysts expect the FDA approval to serve as a catalyst for Kolmar Korea to secure premium suncare orders from multinational cosmetics corporations (MNCs).
Kolmar Korea Expands US Production with Pennsylvania Plant
Kolmar Korea began full-scale operations of its second US plant—Kolmar USA Plant 2—in Pennsylvania in the second half of last year, with an annual production capacity of 300 million units. The facility focuses on producing basic skincare and suncare products, functioning as a key outpost to bypass US tariff barriers and strengthen the local supply chain, accelerating the company's North American market strategy. While orders from existing core clients in the US market slowed somewhat, the company is defending against revenue declines by attracting new clients.
In China, the subsidiary is aggressively onboarding new clients including indie brands and is expected to record stable sales growth of around 10% year-over-year. Park Jong-hyun, a Daol Investment & Securities analyst, noted that despite steep growth among top clients, Kolmar Korea maintains the top five clients' share of Korean subsidiary revenue at around 30%, achieving balanced growth without dependence on any single customer.
Subsidiary Yeonwoo Expected to Turn Profitable Within the Year
Key subsidiaries are showing clear performance turnarounds, reinforcing Kolmar Korea's downside resilience. Yeonwoo, a cosmetics container manufacturing subsidiary that struggled with rising raw material costs and weak demand, is likely to return to profitability within the year thanks to expanded orders centered on indie brands and continuous cost-reduction efforts. Pharmaceutical subsidiary HK innoN is also performing as a cash cow, supported by indication expansion of its blockbuster gastroesophageal reflux disease drug 'K-CAB' and solid revenue growth in the Health & Beauty (H&B) business unit.
FAQ
What drove Kolmar Korea stocks to rise 31% in one week?
Kolmar Korea stocks surged over 31% during the week of June 26 to July 2, driven by analyst forecasts of a Q2 earnings surprise. Securities firms project the Korean production subsidiary will achieve sales growth of 25–26% and a record-high operating profit margin of 15%, fueled by strong suncare and skincare orders from top clients and improved product mix.
What is Bemotrizinol and why does FDA approval matter for Kolmar Korea?
Bemotrizinol is a high-performance organic UV filter that blocks both UVA and UVB rays. The FDA approved it for OTC sunscreen use last month—the first new active UV ingredient approved in 27 years. Kolmar Korea has extensive expertise in formulating and manufacturing sunscreens with this ingredient, positioning the company to secure premium suncare contracts from global multinational cosmetics firms.
How is Kolmar Korea expanding its US production capacity?
Kolmar Korea launched its second US plant in Pennsylvania in the second half of last year, with an annual production capacity of 300 million units. The facility specializes in basic skincare and suncare products, enabling the company to bypass US tariff barriers, strengthen local supply chains, and accelerate market penetration in North America.
